Category: MedtronicSyndicate content

Will Stryker bid on Smith & Nephew this week?

November 24, 2014 by Brad Perriello

Speculation mounts again about a possible Stryker offer for Smith & Nephew now that a 6-month no-bid period has ended.

Will Stryker bid on Smith & Nephew this week?

Medtronic realigns diabetes unit

November 21, 2014 by Brad Perriello

Medtronic reshapes its diabetes business into 3 divisions 'focused on transforming diabetes care,' CEO Omar Ishrak said this week.

Medtronic realigns diabetes unit

Medtronic (NYSE:MDT) said this week that it realigned its diabetes business to focus on "transforming diabetes care," according to CEO Omar Ishrak.

Medtronic CEO Ishrak defends Covidien deal

November 20, 2014 by Scott Wooldridge

Medtronic CEO Omar Ishrak, speaking yesterday at LifeScience Alley's annual convention in Minneapolis, defends the pending $43 billion Covidien acquisition.

Medtronic CEO Ishrak defends Covidien deal

Shares soar for InVivo after spinal cord study update | Medtech Wall Street news for the week of November 17, 2014

November 20, 2014 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: InVivo shares soar on spinal cord study update; Actavis trumps Valeant with $66B offer for Allergan; Medtronic's Q2 results meet The Street; Venture capital investment in medtech grows in Q3

InVivo shares soar on spinal cord study update

November 13, 2014 by Val Kennedy

MDT prepares $10B worth of bonds to help fund its $43B acquisition of COV | The week in medtech M&A

November 19, 2014 by MassDevice

Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Report: Medtronic readies $10B bond flotation for Covidien deal; Medtech mergers stayed strong in Q3; Sources: Philips attracts private equity bids for lighting unit; Medtronic, Covidien set timetable for shareholders meetings; Report: Actavis may buy Allergan for at least $60 billion

Report: Medtronic readies $10B bond flotation for Covidien deal

November 17, 2014 by Brad Perriello

Medtronic hits 52-week high on strong Q2 results

November 18, 2014 by Brad Perriello

Medtronic's strong fiscal 2nd-quarter results pushed its stock to a 52-week high today.

Medtronic hits 52-week high on strong Q2 results

Shares of Medtronic (NYSE:MDT) hit a 52-week high today on the strength of its 2nd-quarter results, peaking at $72.74 apiece.

MDT shares closed at $72.47 each, for a 4.7% gain on the day.

Medtronic's Q2 results meet The Street

November 18, 2014 by Brad Perriello

Medtronic reports fiscal 2nd-quarter sales and earnings in line with expectations on Wall Street.

Medtronic's Q2 results meet The Street

Medtronic (NYSE:MDT) today reported 2nd-quarter results that met expectations on Wall Street.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp